COCPCocrystal Pharma, Inc.

Nasdaq cocrystalpharma.com


$ 1.41 $ -0.10 (-6.67 %)    

Thursday, 28-Mar-2024 15:58:51 EDT
QQQ $ 443.93 $ -0.82 (-0.18 %)
DIA $ 397.72 $ 0.20 (0.05 %)
SPY $ 523.07 $ -0.10 (-0.02 %)
TLT $ 94.55 $ -0.08 (-0.08 %)
GLD $ 205.72 $ 2.62 (1.29 %)
$ 1.4
$ 1.50
$ 0.00 x 0
$ 0.00 x 0
$ 1.41 - $ 1.50
$ 1.33 - $ 3.29
83,047
na
13.51M
$ -0.22
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-28-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-29-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-11-2022 03-31-2022 10-Q
9 03-23-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
12 05-17-2021 03-31-2021 10-Q
13 03-17-2021 12-31-2020 10-K
14 11-13-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-13-2020 03-31-2020 10-Q
17 03-27-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-09-2019 06-30-2019 10-Q
20 05-10-2019 03-31-2019 10-Q
21 04-01-2019 12-31-2018 10-K
22 11-09-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-21-2018 12-31-2017 10-K
26 11-08-2017 09-30-2017 10-Q
27 08-08-2017 06-30-2017 10-Q
28 05-10-2017 03-31-2017 10-Q
29 03-31-2017 12-31-2016 10-K
30 11-09-2016 09-30-2016 10-Q
31 08-09-2016 06-30-2016 10-Q
32 05-10-2016 03-31-2016 10-Q
33 03-15-2016 12-31-2015 10-K
34 11-16-2015 09-30-2015 10-Q
35 08-14-2015 06-30-2015 10-Q
36 05-14-2015 03-31-2015 10-Q
37 03-31-2015 12-31-2014 10-K
38 11-14-2014 09-30-2014 10-Q
39 08-14-2014 06-30-2014 10-Q
40 05-15-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cocrystal-pharma-q4-eps-044-beats-060-estimate

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0....

 hc-wainwright--co-reiterates-buy-on-cocrystal-pharma-maintains-10-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cocrystal Pharma (NASDAQ:COCP) with a Buy and maintains $10 pr...

 cocrystal-pharma-receives-pre-ind-responses-from-the-fda-on-oral-cc-42344-for-treating-influenza-a

Feedback provides greater clarity on regulatory requirements for planned Phase 2b trialBOTHELL, Wash., March 19, 2024 (GLOBE NE...

 cocrystal-pharma-provides-an-update-on-the-clinical-development-of-its-novel-broad-spectrum-antiviral-investigational-candidates

Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") provides an update on the clinical developm...

 hc-wainwright--co-maintains-buy-on-cocrystal-pharma-lowers-price-target-to-10

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cocrystal Pharma (NASDAQ:COCP) with a Buy and lowers the price ...

 hc-wainwright--co-reiterates-buy-on-cocrystal-pharma-maintains-12-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cocrystal Pharma (NASDAQ:COCP) with a Buy and maintains $12 pr...

 cocrystal-pharma-announces-the-presentation-of-data-demonstrating-the-activity-of-its-potent-broad-spectrum-pb2-inhibitor-cc-42344-against-pandemic-and-seasonal-influenza-a-strains-at-the-world-vaccine-congress-west-coast

Cocrystal has initiated a Phase 2a human challenge trial with oral CC-42344 in the UK in subjects infected with influenza A, an...

 cocrystal-pharma-q3-eps-041-beats-053-estimate

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0....

 cocrystal-pharma-receives-uk-mhra-authorization-to-initiate-its-phase-2a-influenza-human-challenge-trial-with-oral-pb2-inhibitor-cc-42344

Cocrystal Pharma, Inc. (NASDAQ:COCP) (Cocrystal or the Company) announces receipt of authorization from the United Kingdom Medi...

 hc-wainwright--co-reiterates-buy-on-cocrystal-pharma-maintains-12-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cocrystal Pharma (NASDAQ:COCP) with a Buy and maintains $12 pr...

 hc-wainwright--co-reiterates-buy-on-cocrystal-pharma-maintains-12-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cocrystal Pharma (NASDAQ:COCP) with a Buy and maintains $12 pr...

 cocrystal-pharma-q2-eps-050-beats-058-estimate

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0....

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION